Praxis Precision Medicines
PRAX
80 hedge funds and large institutions have $751M invested in Praxis Precision Medicines in 2021 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 38 increasing their positions, 10 reducing their positions, and 12 closing their positions.
280% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 10
100% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 12
18% more funds holding
Funds holding: 68 → 80 (+12)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.04% less ownership
Funds ownership: 6.33% → 6.29% (-0.04%)
37% less capital invested
Capital invested by funds: $1.19B → $751M (-$437M)
53% less call options, than puts
Call options by funds: $111K | Put options by funds: $236K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$45.7M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$36.6M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$15.5M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$12.6M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$10.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Blackstone Inc
New York
|
-$64.5M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$36.6M |
| 3 |
State Street
Boston,
Massachusetts
|
-$9.04M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$5.05M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$4.25M |
PRAX Hedge Fund Activity: Q2 2021 in Review
80 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q2 2021, worth a combined $751M — down 37% from $1.19B a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new PRAX positions and 12 closed out — a net gain of 12 holders — while 38 added to existing stakes and 10 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $45.7M. The largest seller was Blackstone Inc, cutting an estimated $64.5M.
- 80 institutional investors held Praxis Precision Medicines (PRAX) as of Q2 2021, up from 68 in Q1 2021.
- Funds reported $751M of Praxis Precision Medicines stock for Q2 2021, down 37% quarter-over-quarter.
- 24 funds opened new Praxis Precision Medicines positions in Q2 2021 and 12 closed out, a net change of +12 holders.
- The largest Praxis Precision Medicines buyer in Q2 2021 was Janus Henderson Group, an estimated $45.7M added.
- The largest Praxis Precision Medicines seller in Q2 2021 was Blackstone Inc, an estimated $64.5M sold.
Based on aggregated 13F filings for Q2 2021.